94 related articles for article (PubMed ID: 28100396)
21. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
22. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ceribelli M; Hou ZE; Kelly PN; Huang DW; Wright G; Ganapathi K; Evbuomwan MO; Pittaluga S; Shaffer AL; Marcucci G; Forman SJ; Xiao W; Guha R; Zhang X; Ferrer M; Chaperot L; Plumas J; Jaffe ES; Thomas CJ; Reizis B; Staudt LM
Cancer Cell; 2016 Nov; 30(5):764-778. PubMed ID: 27846392
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
25. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
26. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
[TBL] [Abstract][Full Text] [Related]
27. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
Qiu H; Jackson AL; Kilgore JE; Zhong Y; Chan LL; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2015 Mar; 6(9):6915-30. PubMed ID: 25762632
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL.
Loosveld M; Castellano R; Gon S; Goubard A; Crouzet T; Pouyet L; Prebet T; Vey N; Nadel B; Collette Y; Payet-Bornet D
Oncotarget; 2014 May; 5(10):3168-72. PubMed ID: 24930440
[TBL] [Abstract][Full Text] [Related]
29. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
Ahmadi SE; Rahimi S; Zarandi B; Chegeni R; Safa M
J Hematol Oncol; 2021 Aug; 14(1):121. PubMed ID: 34372899
[TBL] [Abstract][Full Text] [Related]
30. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Jeong KC; Ahn KO; Yang CH
Mol Biosyst; 2010 Aug; 6(8):1503-9. PubMed ID: 20485733
[TBL] [Abstract][Full Text] [Related]
31. Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation.
Nakamura Y; Kayano H; Kakegawa E; Miyazaki H; Nagai T; Uchida Y; Ito Y; Wakimoto N; Mori S; Bessho M
Blood Cancer J; 2015 Apr; 5(4):e301. PubMed ID: 25860292
[No Abstract] [Full Text] [Related]
32. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Shen A; Wang L; Huang M; Sun J; Chen Y; Shen YY; Yang X; Wang X; Ding J; Geng M
Cancer Res; 2015 Nov; 75(21):4548-59. PubMed ID: 26483207
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
34. Effect of recombinant human endostatin on the expression of c-Myc and bFGF in mouse gastric cancer cells.
Guo ZY; Yao GD; Fu LP; Fu ZG; Hou B
Genet Mol Res; 2015 May; 14(2):5258-65. PubMed ID: 26125720
[TBL] [Abstract][Full Text] [Related]
35. Necdin is a breast cancer metastasis suppressor that regulates the transcription of c-Myc.
Lee M; Beggs SM; Gildea D; Bupp S; Lichtenberg J; Trivedi NS; ; Hu Y; Bodine DM; Crawford NP
Oncotarget; 2015 Oct; 6(31):31557-68. PubMed ID: 26384308
[TBL] [Abstract][Full Text] [Related]
36. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
37. Getting to grips with c-Myc.
Eick D
Elife; 2018 Jan; 7():. PubMed ID: 29313487
[TBL] [Abstract][Full Text] [Related]
38. Cancer research: Open ambition.
Maxmen A
Nature; 2012 Aug; 488(7410):148-50. PubMed ID: 22874946
[No Abstract] [Full Text] [Related]
39. First drugs found to inhibit elusive cancer target.
Moyer MW
Nat Med; 2011 Nov; 17(11):1325. PubMed ID: 22064391
[No Abstract] [Full Text] [Related]
40. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
